As of mid-2025, retatrutide has not received marketing authorisation from the MHRA or EMA and is not available through the NHS or licensed private prescribers
Evidncias cientficas disponveis so majoritariamente pr-clnicas: A maior parte dos estudos foi realizada em modelos animais, nos quais foram observados efeitos sobre cicatrizao, inflamao e proteo tecidual, sem validao robusta em humanos
Their soothing, barrier-friendly profile can suit acne-prone skin, but they are not a dedicated acne treatment
The inclusion of glucagon agonism was initially counterintuitive, but research suggests that when combined with GLP-1 and GIP activity, the net metabolic effect may be beneficial rather than hyperglycemic
Very interesting data High-intensity interval training and moderate-intensity continuous training are both safe and efficacious in improving MASLD Unfortunately, in many patients this kind of training may not be feasible #training #exercise #MASH #weightloss To view or add a comment, sign in Projected Obesity Pharmacotherapy Landscape Through 2029 The obesity treatment landscape is expected to change substantially by 2029, driven by innovative oral and injectable incretin-based therapies that aim to improve efficacy, convenience, and long-term metabolic health
Indias surging demand for GLP-1 weight-loss drugs has spawned a parallel commercial category on e-commerce platforms such as Amazon and Flipkart products marketed under the drugs name that have nothing to do with it